NTNina V. Tsvetaeva

Nina V. Tsvetaeva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nina V. Tsvetaeva has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pattern of T-Lymphocyte Subpopulation in Patients with Cold Agglutinin Disease

    by Polina Igorevna Vasilchenkova, M. N. Finyakina, O. F. Nikulina, N. V. Tsvetaeva, S. M. Kulikov, I. V. Galtseva, E. A. Lukina

    BACKGROUND. Cold agglutinin disease (CAD) is an orphan hematologic disease characterized mainly by hemolytic anemia, increased titer of cold antibodies, and clonality of B-lymphocytes in peripheral blood or/and bone marrow. The role of T-cell population imbalance in CAD has not been studied due to the rarity of this disease and extreme heterogeneity of its clinical and laboratory manifestations. AIM. To analyze the pattern of T-lymphocyte subpopulation in CAD patients and to assess the information value of immune parameters for predicting the treatment efficacy and relapse risk. MATERIALS & METHODS. Over the period from 2020 to 2023, 128 patients with autoimmune hemolytic anemia were examined and treated at the National Research Center for Hematology, the CAD diagnosis was confirmed in 25 of them. The control group consisted of 57 healthy blood donors. RESULTS. Primary CAD patients showed significant decrease of naïve and central memory T-cells compared to similar subpopulations in donors. In 3 and 6 months after completion of immunosuppressive therapy with rituximab, CAD patients had a significant increase of T-helpers and cytotoxic T-lymphocytes as well as a decrease of T-regulatory cells. Among T-helper subpopulations, an increase in Th2 and Th17 cells was reported. The patients who achieved complete hematologic response prior to rituximab therapy, demonstrated a significant increase in Th22 cells. After 3 months of treatment, non-responders showed a drastic increase in cytotoxic T-lymphocytes followed by a decrease to baseline. CONCLUSION. The analysis of the phenotypic spectrum of T-cells demonstrated the difference between the count of naïve and central memory T-cells in CAD patients and healthy donors. This study revealed no significant association of these parameters with the response to immunosuppressive therapy. The only factor associated with achieving complete hematologic response to rituximab was a higher Th22 baseline level compared to donor population.

  • Open Access

    Iron Metabolism in Patients with Paroxysmal Nocturnal Hemoglobinuria: Results of a Single-Center Ambispective Clinical Trial

    by Vitalii Dmitrievich Latyshev, K. A. Jennewein, А. А. Соловьева, A. E. Kitsenko, N. V. Tsvetaeva, E. A. Lukina

    BACKGROUND. Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal hematologic disease manifesting among others in hemolytic anemia. Due to predominantly intravascular hemolysis, iron metabolism in PNH patients is characterized by a number of features. Pathogenetic treatment with complement C5-inhibitors modifies the course of hemolysis and results in iron metabolic changes. AIM. To characterize the serum parameters of iron metabolism in PNH patients and to evaluate T2* MRIs of the liver and kidneys. MATERIALS & METHODS. Serum parameters of iron metabolism measured in 97 analyses and 99 T2* MRIs of the liver and kidneys were assessed in 82 PNH patients treated at the National Research Center for Hematology from 2018 to 2024. Patients were 21–76 years of age (median 39 years); there were 38 women and 44 men. RESULTS. The analysis focused on the data from 78 PNH patients. Among non-recipients of C5-inhibitors, iron overload in liver tissue was identified in 10/38 (26.3 %) patients. In C5-inhibitor recipients, iron overload in liver tissue was found significantly more often, i.e. in 28/40 (70 %) patients. Iron overload in liver tissue was more pronounced in patients with suboptimal hematologic response to PNH therapy. A renal T2* MRI was performed in 71 patients. In all non-recipients of C5-inhibitors (n = 34), iron overload in renal tissue was detected. In C5-inhibitor recipients, iron overload in renal tissue occurred significantly less often, i.e. in 21/37 (57 %) patients. CONCLUSION. Iron overload in renal cortex was identified in all PNH patients who were not treated with C5-inhibitors. Iron overload in liver tissue was associated with blood transfusions and suboptimal hematologic response to pathogenetic PNH therapy. In evaluating iron overload in liver and renal tissues, laboratory methods for assessing iron metabolism in PNH patients have lower sensitivity compared to T2* MRI. In PNH patients, the achievement of optimal response to C5-inhibitor treatment is associated with a decrease in severity of iron overload in renal tissue and no hepatic hemosiderosis.

  • Open Access

    Hematological response in patients with paroxysmal nocturnal hemoglobinuria treated with C5-inhibitor

    by V. D. Latyshev, Z. T. Fidarova, R. V. Ponomarev, N. V. Tsvetaeva, E. A. Mikhaylova, E. A. Lukina, E. N. Parovichnikova

    Background. Paroxysmal nocturnal hemoglobinuria is a rare clonal disease of the hematopoietic system, with the key manifestations of hemolytic anemia, a high thrombosis rate, and bone marrow failure. Despite the high efficacy of C5‑inhibitors in intravascular hemolysis cessation, a significant proportion of patients remain anemic. Causes of a sub‑optimal response may include C3‑mediated extravascular (intracellular) hemolysis, residual intravascular hemolysis, or bone marrow failure.Aim. To analyze the results of pathogenetic therapy in patients with paroxysmal nocturnal hemoglobinuria.Materials and methods. The study included 55 patients with paroxysmal nocturnal hemoglobinuria receiving complement C5 inhibitors for at least 6 months. Results. Suboptimal hematological response was observed in 31/55 (56 %) patients. The most common cause of anemia in the partial response group was C3‑mediated extravascular hemolysis in 8/10 (80 %), while bone marrow failure predominated (57 %) in the minor response group.Conclusion. The study showed a high frequency of suboptimal response to pathogenetic therapy and necessity of ac‑curate determination of leading cause of persistent anemia in order to modify therapy or switch to other drugs.


  • Open Access

    Iron deficiency anemia in a patient with hereditary hemorrhagic telangiectasia. Case report

    by Maria A. Mozdon, Rodion V. Ponomarev, Nina V. Tsvetaeva, Aleksey V. Shabrin, Evgeniya I. Ermachenkova, Sergei E. Larichev, Elena A. Lukina

    RenduOslerWeber disease or hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant disease. It is characterized by vascular dysplasia with the formation of telangiectasias on the skin, mucous membranes of the respiratory and digestive tracts, arteriovenous malformations (AVMs) in the internal organs, which is manifested by bleeding. Diagnosis is based on Curacao criteria: recurrent and spontaneous nosebleeds, multiple telangiectases on the characteristic localizations, AVMs in one or more of the internal organs, a family history of HHT (i.e. first-degree relative who meets these same criteria for definite HHT). Therapy is aimed at preventing and stopping gastrointestinal, nosebleeds, correction of iron deficiency anemia. A promising method of therapy is the use of angiogenesis inhibitors, in particular bevacizumab. The article presents a description of a clinical case of HHT in a 49-year-old woman with telangiectisia on the mucous membrane of the tongue, gastrointestinal tract and liver AVMs.


  • Open Access

    Clinical guidelines for the management of patients with paroxysmal nocturnal hemoglobinuria

    by V. G. Savchenko, E. A. Lukina, E. A. Mikhaylova, N. V. Tsvetaeva, V. D. Latyshev, K. A. Lukina, Z. T. Fidarova, I. V. Galtseva, V. N. Dvirnik, V. V. Ptushkin, et al.

    Introduction. Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal disease of the blood system characterized by intravascular hemolysis, bone marrow dysfunction and an increased risk of thrombotic and organ complications.Aim — to provide relevant clinical recommendations for the provision of medical care to adults and children with PNH.Basic information. Experts from the National Hematological Society association which is focused on the promotion of hematology, transfusiology and bone marrow transplantation along with experts from the public organization, National Society of Pediatric Hematologists and Oncologists, have developed current clinical recommendations for providing medical care to adults and children with PNH. The recommendations address in detail the issues of etiology, pathogenesis, epidemiology, and clinical manifestations of the disease. Special attention is paid to the diagnosis, differential diagnosis, and treatment of PNH based on the principles of evidence.


  • Open Access

    Thrombotic thrombocytopenic purpura in pregnancy. Giving birth or not giving birth, that is the question

    by G. M. Galstyan, R. G. Shmakov, Е. Е. Klebanova, V. V. Troitskaya, V. N. Dvirnyk, V. L. Surin, O. S. Pshenichnikova, Yu. M. Pozdnyakova, E. S. Polushkina, T. V. Gaponova, et al.

    Introduction. Pregnancy is one of the most frequent triggers of congenital and acquired forms of thrombotic thrombocytopenic purpura (TTP).Aim — to develop tactics for the treatment of pregnant women with TTP.Results. TTP was associated with pregnancy in 55.5 % of all cases of TTP in women. In 5 pregnancies in which the diagnosis of TTP was known before pregnancy, or established in the early stages, TTP was treated throughout the pregnancy. In the congenital form, plasma transfusions were performed once every two weeks until the 20th week of pregnancy, or weekly, if thrombocytopenia < 150 × 109 /L persisted. Plasma transfusions were performed weekly after the 20th week with the goal of achieving clinical remission. With acquired TTP, glucocorticosteroids and plasma exchanges were used as treatment, in 1 case — rituximab, with the aim of achieving a clinical remission and an ADAMTS13 activity > 20 %. In this group of pregnant women, 1 caesarean section was performed and there were 4 cases of vaginal deliveries, with a total of 5 children being born with an average Apgar score of 7.5. In 7 pregnancies in which TTP fi rst manifested late, leading to a delayed diagnosis, preventive and curative measures were not carried out before delivery. In this group there were 2 abortions of pregnancy, 5 surgical deliveries, 3 cases of preeclampsia, 3 acute cerebral circulatory disorders, 1 intraabdominal bleeding, 1 case of acute renal failure, with two women undergoing mechanical ventilation. There was 1 case of antenatal fetal death, with a total of 4 children being born, who were assessed on the Apgar scale with an average of 5 points.Conclusion. Timely diagnosis as well as ongoing therapeutic and preventive measures help to avoid complications during childbirth in pregnant women with TTP.


  • Open Access

    Radioiodine therapy outcome in toxic multinodular goiter patient with concomitant hereditary Hasharon hemoglobinopathy

    by Dali S. Dzeytova, Stanislav S. Shklyaev, Pavel O. Rumyantsev, Marina S. Sheremeta, Alexey A. Trukhin, Nina V. Tsvetaeva, Evgenii E. Kozhedub, Трухин Алексей Андреевич

    This research describes a clinical case of treatment of a patient with thyrotoxicosis with concomitant hematological pathology carriage of unstable hemoglobin Hasharon. A patient diagnosed with Diffuse toxic nodular goiter. Thyrotoxicosis of medium severity. Drug-induced hypothyroidism was admitted to the Department of radionuclide therapy for the purpose of treatment with radioactive iodine. Onset of disease - summer 2018 (thyroid-stimulating hormone (TSH) 0 mIU/ml). The instrumental studies (ultrasound, scintillation scanning of the thyroid gland) were performed at the pre-radioiodine therapy (RIT) diagnostic stage. The history of the disease indicates, that in 2000 the patient was suspected of having abnormal hemoglobin, since then no examinations have been conducted and anemia has never been detected. The diagnosis of ancestral hemoglobinopathy with the presence (17%) of unstable Hasharon-Sinai-Sealy hemoglobin in a heterozygous form was verified during the preparation to RIT. The radionuclide therapy I131 with activity of 400 MBq was performed on 02.07.2019. The monthly monitoring of laboratory and instrumental indicants was carried out during the post-therapeutic period: the state of hypothyroidism was reached by the end of 2 months after RT, no episodes of significant increase in bilirubin levels were observed during the observation period; no side effects from RT were stated. It becomes possible based on the example of the above observation, to judge the safety of conducting RT for treatment of thyrotoxicosis in patients with similar hemoglobinopathy, without excluding, however, the need for an individual approach in each case.

  • Open Access

    The non-compacted myocardium in patients with hemochromatosis: a phenomenon or cardiopathy? The role of magnetic resonance imaging and molecular genetics in diagnosis

    by E. A. Mershina, O. V. Kulikova, R. P. Myasnikov, E. A. Lukina, A. N. Meshkov, A. V. Kiseleva, P. S. Pilyus, S. N. Koretsky, M. S. Kharlap, R. V. Ponomarev, et al.

    This article presents the results of studies on high prevalence of left ventricular noncompaction (LVNC) in patients with secondary hemochromatosis (SH). We also included case reports of patients with SH and LVNC and compared imaging data using modified modern criteria for LVNC and molecular genetic testing (MGT). In patients with cardiac hemochromatosis, left ventricular noncompaction is noted, the nature of which is most likely secondary. In order to confirm this hypothesis, a prospective observational study, including family screening and MGT, is required.